関連する実験動画
Updated: Jun 19, 2026

06:35
Basics of Multivariate Analysis in Neuroimaging Data
Published on: July 25, 2010
機能的および臨床的:多峰性アルツハイマー病分類のための説明可能なディープラーニングモデル
Samuel L Warren1, Ahmed A Moustafa1,2
1School of Psychology, Faculty of Society and Design, Bond University, Gold Coast, Queensland, Australia.
Brain and behavior
|January 30, 2026
まとめ
機能的磁気共鳴画像法(fMRI)と臨床データを組み合わせることで、ディープラーニングを用いたアルツハイマー病(AD)分類が大幅に向上します。この多峰性アプローチは、より良い臨床応用のためにモデルの精度と説明可能性を高めます。
科学分野:
- 神経画像;人工知能;臨床診断
背景:
- fMRIを使用したディープラーニングモデルは、アルツハイマー病(AD)の分類に有望です。課題には、小規模なデータセット、説明可能性の欠如、データリークなどの信頼性の問題が含まれ、臨床応用を妨げています。
主な方法:
- デフォルトモードネットワークのfMRIデータと5つの臨床検査を使用して、3D畳み込みニューラルネットワークをトレーニングしました。多峰性データの統合と厳密なLeave-one-out交差検証を使用して、データ制限を克服し、データリークを防ぎました。特徴の重要性分析のために摂動ランキングを適用しました。
結論:
- 多峰性ディープラーニングモデルでfMRIと臨床データを組み合わせることで、AD分類の精度が向上し、疾患の特徴に関する洞察が得られます。開発されたモデルは、アルツハイマー病の診断ツールの改善の可能性を示しています。より大規模なサンプルサイズでのさらなる外部検証が推奨されます。
関連する概念動画
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
